Figure 3 | Scientific Reports

Figure 3

From: Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis

Figure 3

(A) Three-year overall survival (OS) rates comparing subjects with and without TB. No statistically significant difference was found between subjects with and without TB (57.14% vs 76.79%; P = 0.102); (B)Three-year nonrelapse mortality (NRM) cumulative incidence curve. Grey’s competing risk method revealed a significantly higher 3-year NRM in subjects with TB compared to that of subjects without TB (30.36% ± 13.55% vs 5.39% ± 3.06%, P = 0.002).

Back to article page